Could adding warfarin save bypass grafts? new trial investigates.

NCT ID NCT05782270

Recruiting now Disease control Sponsor: China National Center for Cardiovascular Diseases Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two blood-thinning strategies after a combined heart bypass and endarterectomy procedure. About 202 adults with widespread coronary artery disease will receive either standard dual antiplatelet therapy or that therapy plus warfarin. The goal is to see if adding warfarin keeps the bypass grafts open longer without causing dangerous bleeding.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Warfarin plus dual antiplatelet therapy (aspirin and clopidogrel or ticagrelor)
What this could lead to: If it works, this could point toward a better way to prevent graft failure after complex heart surgery.
What could go wrong: This is a moderate-sized Phase 4 trial, so results may not apply to all patients. Adding warfarin raises bleeding risk, which could outweigh benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTICOAGULATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTICOAGULATION CORONARY ENDARTERECTOMY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITING

Beijing, Beijing Municipality, 100037, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.